利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.012 秒)

    ATTENUATED DENGUE VIRUSES
    5.
    发明申请
    ATTENUATED DENGUE VIRUSES 有权

    公开(公告)号：US20220347285A1

    公开(公告)日：2022-11-03

    申请号：US17621125

    申请日：2020-06-23

    申请人： CODAGENIX INC.

    发明人： Steffen Mueller ,  John Robert Coleman ,  Charles Stauft ,  Ying Wang

    IPC分类号： A61K39/12 ,  C12N7/00 ,  A61P31/14

    摘要： The present invention provides for modified Flavivirus such as a modified dengue virus type 1, 2, 3, 4, a combination of these, or a tetravalent combination of these. The modification according to various aspects of the invention results in reduced viral protein expression compared to a parent virus, wherein the reduction in expression is the result of recoding one or more regions of the virus. For example, the prM, or envelope (E) region can be recoded. In various embodiments one or more regions are recoded by reducing the codon pair bias or codon usage bias of the protein-encoding sequence. These modified Flaviviruses are used as vaccine compositions to provide a protective immune response.

    RECOMBINANT VIRUS WITH CODON-PAIR DEOPTIMIZED REGION AND USES THEREOF FOR THE TREATMENT OF CANCER
    6.
    发明申请
    RECOMBINANT VIRUS WITH CODON-PAIR DEOPTIMIZED REGION AND USES THEREOF FOR THE TREATMENT OF CANCER 有权

    公开(公告)号：US20210228705A1

    公开(公告)日：2021-07-29

    申请号：US16769102

    申请日：2018-12-21

    申请人： CODAGENIX INC.

    发明人： John Robert Coleman ,  Steffen Mueller ,  Chen Yang ,  Ying Wang ,  Charles Stauft

    IPC分类号： A61K39/13 ,  A61K39/145 ,  C12N7/00

    摘要： The present invention is the use of designed recombinant viruses for the treatment of various forms of malignant tumors. The recombinant viruses of the invention are those in which one or more regions of the wild type virus was exchanged with a synthetic recoded sequence that reduces the codon pair score relative to human codon pair bias, or that increase the number for CpG di-nucleotides, or that increases the number of UpA di-nucleotides. The method of the present invention is particularly useful for the treatment of malignant tumors in various organs, such as: breast, skin, colon, bronchial passage, epithelial lining of the gastrointestinal, upper respiratory and genito-urinary tracts, liver, prostate and the brain. Astounding remissions in experimental animals have been demonstrated for the treatment of malignant glioblastoma multiforme, as well as for the treatment of breast cancer and melanoma as well.

    ATTENUATED FLAVIVIRUSES
    9.
    发明申请
    ATTENUATED FLAVIVIRUSES 有权

    公开(公告)号：US20210000939A1

    公开(公告)日：2021-01-07

    申请号：US16976220

    申请日：2018-12-21

    申请人： Codagenix Inc.

    发明人： John Robert Coleman ,  Steffen Mueller ,  Ying Wang

    IPC分类号： A61K39/12 ,  C12N7/00 ,  A61P31/14

    摘要： The present invention provides for modified Flavivirus such as a modified Zika virus. The modification according to various aspects of the invention results in reduced viral proteins compared to a parent virus, wherein the reduction in expression is the result of recoding one or more regions of the virus. For example, the prM, or envelope (E) region, or the nonstructural protein 3 (NS3) region or both the E and NS3 regions can be recoded. In various embodiments one or more regions are recoded by reducing the codon pair bias or codon usage bias of the protein-encoding sequence. These modified Flavivirus are used as vaccine compositions to provide a protective immune response.